23 June 2020 - SHS News

SHS appoints Heinz Jacqui Senior Advisor

Heinz Jacqui (59) has been appointed Senior Advisor at SHS Gesellschaft für Beteiligungsmanagement effective June 1, 2020. By way of succession arrangements or growth financing, SHS specializes in investing in innovative healthcare companies that focus on medical technology and the life sciences. Through several funds, SHS has more than EUR 300 million under management. It has invested in more than 60 companies since it was established in 1993. At SHS, Jacqui, who has previously held executive positions at Maquet, Olympus and Dräger, will play a particular role in the strategic positioning of firms in medical technology and in entries into new investments.

Since receiving his degree in engineering, Heinz Jacqui has held several positions in the field of medical technology in a career spanning more than 30 years. As Global Business Unit President of Dräger Medical, he oversaw the Critical Care, Architectural Systems and Neonatal Care divisions. Working from Shanghai, for four years Jacqui managed the China trade for Dräger Medical. His next steps led him to Olympus Medical, where, as Executive Vice President, he was responsible for the global laparoscopy business. Following this position, Jacqui was named President & CEO at Maquet/Getinge, where he oversaw the global medicine business.

“We are very pleased to have recruited Heinz Jacqui as Senior Advisor for SHS,” SHS Managing Partner Hubertus Leonhardt remarked. “His many years of strategic experience with companies in the field of medical technology have made him a true asset to us and our portfolio companies. Together, we want to offer strategic support to our portfolio firms, particularly in the fields of cardiology, imaging and intensive-care medicine and review investments in additional firms.”

“SHS has an exciting spread of portfolio companies with strong growth. I look forward to assisting, on a case-by-case basis, with strategic orientation and the initiation of international cooperation arrangements with corporate groups in the medical-technology sector,” Heinz Jacqui noted. “I’m also excited to help explore and evaluate additional investments under the recently launched SHS V fund.”

About SHS Gesellschaft für Beteiligungsmanagement mbH:

SHS Gesellschaft für Beteiligungsmanagement is based in Tuebingen, Germany, and invests in medical technology and life science companies with a focus on expansion financing, changes in shareholder structures and successor situations. SHS holds minority as well as majority interests. The company was founded in 1993 and has since gained extensive experience as an industry investor which supports the growth of its portfolio companies through a network of partnerships regarding the introduction of new products, regulatory issues or entering new markets. The SHS fund’s European based investors include pension funds, strategic investors, funds of funds, family offices, entrepreneurs and the SHS management team. The AIFM-registered company invests up to €30 million in equity capital and volumes exceeding this amount are implemented with a network of co-investors. SHS is currently investing from its fifth fund which received capital commitments of more than €130 million. Further information: http://www.shs-capital.eu/en/

Are you interested in receiving regular updates about SHS? Subscribe to our newsletter!
http://www.shs-capital.eu/en/newsletter/

PR contact:

Regine Hujer
SHS Gesellschaft für Beteiligungsmanagement mbH
Bismarckstrasse 12
72072 Tuebingen
Phone +49 7071 9196-100